<DOC>
	<DOCNO>NCT01908296</DOCNO>
	<brief_summary>The objective study assess effect multiple-dose fluvoxamine pharmacokinetics quetiapine ( FK949E ) healthy adult male subject . The safety FK949E population also evaluate .</brief_summary>
	<brief_title>Study Evaluate Effect Multiple-dose Fluvoxamine Plasma Concentration Quetiapine ( FK949E ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fluvoxamine</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Body weight : ≥50.0 kg , &lt; 80.0 kg Body Mass Index : ≥17.6 , &lt; 26.4 Healthy , judge investigator/subinvestigator base result physical examination ( subjective symptom objective finding ) test obtain screen period hospital admission immediately study medication Subjects follow history . 1 . Hepatic disease ( e.g . viral hepatitis , druginduced liver injury ) . 2 . Heart disease ( e.g . congestive heart failure , angina pectoris , arrhythmia require treatment ) . 3 . Respiratory disease ( e.g . serious bronchial asthma , chronic bronchitis ) 4 . Gastrointestinal disease ( e.g . serious peptic ulcer , gastroesophageal reflux esophagitis ; diseases require several selection except appendicitis ) 5 . Renal disease ( e.g . acute renal failure , glomerulonephritis , interstitial nephritis ) . 6 . Cerebrovascular disorder ( e.g . cerebral infarction ) . 7 . Malignant tumor . 8 . Drug allergy . Allergic disorder ( except hay fever ) 9 . Drug dependence , alcohol dependence Any disease ( except dental caries ) A deviation normal reference range blood pressure , pulse rate , body temperature , 12lead ECG A deviation follow criterion clinical laboratory test . The normal reference range specify study site use normal reference range present study . 1 . Hematology : A deviation ±20 % upper low limit normal range 2 . Blood biochemistry : A deviation normal range AST , ALT , creatinine ( Cre ) , HbA1c serum electrolyte . A deviation ±20 % upper low limit normal range item . However , low limit normal range establish item deviation low limit consider clinically significant [ AST , ALT , total bilirubin ( TBil ) , ALP , γGTP , LDH , CK , Cre , uric acid ( UA ) , BUN , total cholesterol ( TCho ) ] . 3 . Urinalysis : UGlc and/or UPro result ( ± ) bad UUro result ( + ) bad 4 . Urinary drug test : A positive result phencyclidine , benzodiazepine , cocaine , amphetamine , cannabis , opiates , barbiturates tricyclic antidepressant 5 . Immunological test : A positive result hepatitis B , hepatitis C , syphilis , HIV History treatment , include medication , within 14 day start study drug administration Consumption food beverage contain St. John 's Wort within 14 day start study drug administration , consumption grapefruit Previous participation pre postmarketing clinical study another prescription drug medical device within 120 day study History administration quetiapine History administration fluvoxamine Whole blood sample 400 mL within 90 day screen assessment , whole blood sample 200 mL within 30 day screen assessment , blood component donation within 14 day screen assessment Routine excessive alcohol consumption ( `` excessive alcohol '' define average 45 g alcohol per day [ cf. , large bottle beer contain 25 g alcohol , 180 mL sake contain 22 g alcohol ] ) Subjects smoke habit ( except quit smoking least 90 day screen assessment )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FK949E</keyword>
	<keyword>fluvoxamine</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Quetiapine</keyword>
</DOC>